Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page . x Q+ O! Y+ V
5 s% O& U9 v( d9 ]( Y6 c
) F0 C4 } }6 a6 x, K' F, tSub-category:
" ~# L5 f: W; xMolecular Targets
2 ~* H$ _$ _) v9 Y" w8 Q: U$ q1 @( n% u5 ? q$ n4 g
0 H) b9 m6 l' e( l3 J$ L, H$ N- dCategory:/ @4 r) U9 } d" E0 @& j' n0 }
Tumor Biology : z3 F& j. w% W9 P- x! T$ R. P
4 D l7 \6 _3 A9 G) ]/ w1 G+ `8 N: o0 H x
Meeting:
1 a% N( ?* C n. `- r2011 ASCO Annual Meeting
" X O. e/ l) ?! ^
& E) h) Z1 g6 I& C% o
1 _: \ \7 _1 @+ b4 m" qSession Type and Session Title:- S4 x( ]+ [( u& @
Poster Discussion Session, Tumor Biology
! [. ?& U- N' s" F% K3 g( s! p
! u" ^6 R6 d2 W3 h* |' M$ ?" W0 p. b2 l. z& g8 A7 ~5 Z
Abstract No:) R9 a. m' Y0 n4 |
10517
Z2 v+ r$ P2 d+ O" a. T2 U% }4 I) O. Z* R$ r& `
" P0 y* _3 f9 ^) d, Q7 U/ E- TCitation: L) f9 ?+ `7 q+ ?
J Clin Oncol 29: 2011 (suppl; abstr 10517)
9 n& t4 V/ V ]3 W9 H' O% V
( j7 |0 ]. C# P. S3 X; |1 P) R7 p
- x( c1 |- @% t7 W, |( K9 V6 }% {Author(s):- k. l$ p7 @! p4 m
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
2 G/ p+ p% Y* g$ E) i7 T* Z$ O
^% ~/ X$ I8 F2 O7 k+ C, S, E, L% A/ v
Y& p" M! j ^- FAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
$ o* D) x# I- t" ~" Z% V9 O% k' U/ X" ~# j
Abstract Disclosures
9 l5 z! P8 Q/ Y) n! N6 M3 b+ l
! H4 [) Z! }. e: pAbstract:5 X1 y2 y* x0 y. v
, W- P! I0 ?. `6 f! D
# \( ] ^( B2 x) M. H1 b6 `, \, D$ W" E
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
7 L) ]- Z3 [& F
& a1 i! Y% J& s1 z: } * a9 V- v5 [- U# e: ]& Y4 Y
|
显身卡
